We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN - Free Report) agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash. The deal could pave the way for one of the pharmaceutical industry’s largest mergers of the past decade — Bristol-Myers Squibb’s (BMY - Free Report) proposed acquisition of Celgene Corp for $74 billion in a cash-and-stock deal (read: Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus).
Otezla offers huge growth to Amgen as it has patent exclusivity through at least 2028 in the United States. Additionally, the drug will provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits in well with the company’s anti-inflammatory injectable Enbrel, prospects of which got a boost recently after a U.S. judge upheld two patents protecting the drug’s active ingredient until 2029, effectively denying a biosimilar challenge by Novartis AG (NVS - Free Report) .
Further, the acquisition of the psoriasis drug is expected to be accretive to Amgen’s revenues and non-GAAP EPS immediately after the completion of the deal. Otezla's sales are expected to grow at least in the low-double digits over the next five years. The psoriasis drug had generated $1.61 billion in sales last year and is expected to bring in revenues of $2.71 billion in 2023, according to analysts’ estimates compiled by Bloomberg (see: all the Healthcare ETFs here).
ETF Impact
Investors seeking to play Amgen’s strong future growth story could consider ETFs having the largest allocation to this biotech company. We have highlighted some of them in detail below:
This fund offers exposure to 25 large biotechnology corporations by tracking the MVIS US Listed Biotech 25 Index. Amgen is the top firm accounting for 9.9% share. BBH has amassed $343.5 million in its asset base and charges 35 basis points in fees per year. It sees a light volume of 15,000 shares per day on average and has a Zacks ETF Rank #2 (Buy) with a High risk outlook (read: Biotech ETFs in Focus on Impressive Q2 Earnings Results).
This fund provides exposure to 2219 firms by tracking the Nasdaq Biotechnology Index, with AMGN taking the top spot at 9.42%. IBB is the most-popular fund is the biotech space with AUM of $6.7 billion. Expense ratio comes in at 0.47%. The product trades in average daily volume of 2.5 million shares and has a Zacks ETF Rank #2 with a High risk outlook.
This fund follows the Dynamic Biotech & Genome Intellidex Index. It holds 29 stocks in its basket with AMGN occupying the top spot at 6.11% share. It has managed $227.7 million in its asset base while trades in a light volume of 16,000 shares per day. Expense ratio comes in at 0.59%. The product has a Zacks ETF Rank #3 (Hold) with a High risk outlook (read:Pfizer-Array Biopharma Deal Bump Up Biotech ETFs).
With AUM of about $367.4 million, this ETF targets the pharma corner of the broad healthcare sector and follows the Dynamic Pharmaceuticals Intellidex Index. It holds 30 stocks in its basket, with Amgen taking 6.12%. The product trades in average daily volume of 37,000 shares and charges 57 bps in fees and expenses. It has a Zacks ETF Rank #3 with a High risk outlook (read: Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?).
iShares Evolved U.S. Innovative Healthcare ETF
This actively managed ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector. Holding 213 stocks in its basket, BMY takes the seventh spot at 4.45%. The product has accumulated $4.8 million in its asset base and charges 18 bps in annual fees. Volume is light, trading in about 2,000 shares a day on average.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
In-Depth Zacks Research for the Tickers Above
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen to Buy Celgene's Otezla: 5 ETF Drugs
Amgen (AMGN - Free Report) agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash. The deal could pave the way for one of the pharmaceutical industry’s largest mergers of the past decade — Bristol-Myers Squibb’s (BMY - Free Report) proposed acquisition of Celgene Corp for $74 billion in a cash-and-stock deal (read: Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus).
Otezla offers huge growth to Amgen as it has patent exclusivity through at least 2028 in the United States. Additionally, the drug will provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits in well with the company’s anti-inflammatory injectable Enbrel, prospects of which got a boost recently after a U.S. judge upheld two patents protecting the drug’s active ingredient until 2029, effectively denying a biosimilar challenge by Novartis AG (NVS - Free Report) .
Further, the acquisition of the psoriasis drug is expected to be accretive to Amgen’s revenues and non-GAAP EPS immediately after the completion of the deal. Otezla's sales are expected to grow at least in the low-double digits over the next five years. The psoriasis drug had generated $1.61 billion in sales last year and is expected to bring in revenues of $2.71 billion in 2023, according to analysts’ estimates compiled by Bloomberg (see: all the Healthcare ETFs here).
ETF Impact
Investors seeking to play Amgen’s strong future growth story could consider ETFs having the largest allocation to this biotech company. We have highlighted some of them in detail below:
VanEck Vectors Biotech ETF (BBH - Free Report)
This fund offers exposure to 25 large biotechnology corporations by tracking the MVIS US Listed Biotech 25 Index. Amgen is the top firm accounting for 9.9% share. BBH has amassed $343.5 million in its asset base and charges 35 basis points in fees per year. It sees a light volume of 15,000 shares per day on average and has a Zacks ETF Rank #2 (Buy) with a High risk outlook (read: Biotech ETFs in Focus on Impressive Q2 Earnings Results).
iShares Nasdaq Biotechnology ETF (IBB - Free Report)
This fund provides exposure to 2219 firms by tracking the Nasdaq Biotechnology Index, with AMGN taking the top spot at 9.42%. IBB is the most-popular fund is the biotech space with AUM of $6.7 billion. Expense ratio comes in at 0.47%. The product trades in average daily volume of 2.5 million shares and has a Zacks ETF Rank #2 with a High risk outlook.
Invesco Dynamic Biotechnology & Genome ETF (PBE - Free Report)
This fund follows the Dynamic Biotech & Genome Intellidex Index. It holds 29 stocks in its basket with AMGN occupying the top spot at 6.11% share. It has managed $227.7 million in its asset base while trades in a light volume of 16,000 shares per day. Expense ratio comes in at 0.59%. The product has a Zacks ETF Rank #3 (Hold) with a High risk outlook (read:Pfizer-Array Biopharma Deal Bump Up Biotech ETFs).
Invesco Dynamic Pharmaceuticals ETF (PJP - Free Report)
With AUM of about $367.4 million, this ETF targets the pharma corner of the broad healthcare sector and follows the Dynamic Pharmaceuticals Intellidex Index. It holds 30 stocks in its basket, with Amgen taking 6.12%. The product trades in average daily volume of 37,000 shares and charges 57 bps in fees and expenses. It has a Zacks ETF Rank #3 with a High risk outlook (read: Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?).
iShares Evolved U.S. Innovative Healthcare ETF
This actively managed ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector. Holding 213 stocks in its basket, BMY takes the seventh spot at 4.45%. The product has accumulated $4.8 million in its asset base and charges 18 bps in annual fees. Volume is light, trading in about 2,000 shares a day on average.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>